+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD

Clinical Journal of the American Society of Nephrology 9(4): 705-712

Few randomized controlled trials have compared intravenous iron products head to head in CKD patients with iron deficiency anemia. This study compared the efficacy and safety of two intravenous iron products (ferumoxytol [Feraheme injection] and iron sucrose [Venofer]) in patients with CKD and iron deficiency anemia. In this phase II, randomized, open-label, active-controlled, multicenter clinical trial, patients were randomized 1:1 to either 1.02 g ferumoxytol (2 × 510-mg injections) or 1.0 g iron sucrose administered as either a slow injection or infusion (10 doses for dialysis patients and 5 doses for nondialysis patients). Inclusion criteria included hemoglobin<11.0 g/dl, transferrin saturation<30%, and eGFR<60 ml/min per 1.73 m(2) or a diagnosis of underlying CKD (e.g., nephropathy or nephritis). The primary end point was change in hemoglobin from baseline to week 5. In total, 162 patients were randomized. Demographics were balanced between the treatment groups. Adverse event profiles of the two regimens were fairly similar: overall adverse events, 48% ferumoxytol versus 65% iron sucrose; related adverse events, 10% ferumoxytol versus 16% iron sucrose; and adverse events leading to study discontinuation, 1% ferumoxytol versus 5% iron sucrose. Rates of serious adverse events and related serious adverse events were similar between the ferumoxytol and iron sucrose groups: serious adverse events, 9% versus 7%, respectively and related serious adverse events, 1% versus 1%, respectively. Overall, increases in hemoglobin were similar between treatment groups. Based on an ANOVA model adjusted for baseline hemoglobin level and dialysis status, the least squares mean change from baseline to week 5 was 0.8 ± 0.1 g/dl in the ferumoxytol-treated group and 0.7 ± 0.1 g/dl in the iron sucrose group. The difference in the mean change from baseline between the two treatment groups was 0.1 g/dl (95% confidence interval, -0.2 to 0.4). In this randomized, controlled trial, ferumoxytol and iron sucrose showed comparable efficacy and adverse events rates.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051227970

Download citation: RISBibTeXText

PMID: 24458078

DOI: 10.2215/cjn.05320513

Related references

A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. American Journal of Hematology 89(6): 646-650, 2014

Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. Bmc Hematology 16: 20, 2016

Tu1743 Iv Iron Treatment of Iron Deficiency Anemia with Ferumoxytol in Patients with Inflammatory Bowel Disease Unable to Take Oral Iron: A Randomized Controlled Trial Versus Ferric Carboxymaltose. Gastroenterology 156(6): S-1107-S-1108, 2019

The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Bmc Nephrology 18(1): 117, 2017

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. American Journal of Hematology 92(3): 286-291, 2017

Tu1073 Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients With Gastrointestinal Disorders Who Have a History of Unsatisfactory Oral Iron Therapy: Results of a Phase Iii, Randomized, Placebo-Controlled Trial. Gastroenterology 144(5): S-754, 2013

Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. American Journal of Gastroenterology 100(11): 2503-2509, 2005

Ferumoxytol for treating iron deficiency anemia in CKD. Journal of the American Society of Nephrology 19(8): 1599-1605, 2008

O022 Is Intravenous Iron Sucrose An Alternative To The Oral Iron-Folate Supplementation For Treating Iron Deficiency Anemia In Pregnant And Post Natal Women. International Journal of Gynecology & Obstetrics 119: S268-S269, 2012

Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. Journal of Obstetrics and Gynaecology Research 39(2): 504-510, 2013

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
. Clinical Nephrology 91(4): 237-245, 2019

Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. Journal of Maternal-Fetal and Neonatal Medicine 26(7): 654-659, 2013

Prenatal Iron Supplementation Reduces Maternal Anemia, Iron Deficiency, and Iron Deficiency Anemia in a Randomized Clinical Trial in Rural China, but Iron Deficiency Remains Widespread in Mothers and Neonates. Journal of Nutrition 145(8): 1916-1923, 2015

Treatment of iron-deficiency anemia with IV ferumoxytol in CKD patients: Efficacy compared with oral iron across different age groups. 2007

Ferumoxytol: a new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. PharmacoTherapy 30(1): 70-79, 2010